[Lipid profile during specific malaria therapy in Gabonese children].
We report specific dyslipidemia in Gabonese children aged 18 months to 4 years old treated with Halfan for malaria. This is observed in addition to the hypoglycemia typically associated with malaria. C-HDL (high density lipoprotein) fell on day 0 (D0), then increased during the treatment. Triglycerides (TG), total cholesterol (TC) and non-esterified fatty acids (NEFA) rose on D0. CT continued to rise evenly throughout the treatment, whereas TG declined. The differences with respect to normal values are significantly different as assessed by the Student test. We report metabolic variation and tolerance to Halfan.
Ngou-Milama
E
E
Faculté de Médecine, Service parasitologie-médecine tropicale, Tours, France.
Duong
T H
TH
Minko
F
F
Dufillot
D
D
Kombila
M
M
Richard-Lenoble
D
D
Mouray
H
H
D000962:Antimalarials / Q000009:adverse effects*; D016022:Case-Control Studies; D002675:Child, Preschool; D005681:Gabon; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced*; D007223:Infant; D016778:Malaria, Falciparum / Q000097:blood / Q000188:drug therapy*; D010616:Phenanthrenes / Q000009:adverse effects*
D000962:Antimalarials; D010616:Phenanthrenes; C023768:halofantrine
Profil lipidique au cours d'une thérapeutique curative spécifique du paludisme maladie chez l'enfant gabonais.